Spruce Biosciences licenses tildacerfont to Kaken for Japan; $15M upfront, up to $65M milestones

SPRUCE BIOSCIENCES, INC.

Exclusive Japan rights for tildacerfont in CAH; $15M upfront, up to ~$65M in development/regulatory/commercial milestones.
Preliminary cash, cash equivalents and investments as of Dec 31, 2022: approximately $79M (unaudited).
Pediatric CAH trial amended: study length increased to 12 weeks plus 2-year open-label extension; age lowered to 2 years.
Additional data to be collected: PK at 50mg and 200mg doses, A4 reduction, GC reduction, and 12-week safety data.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SPRUCE BIOSCIENCES, INC. entered into Collaboration and License Agreement with Kaken Pharmaceutical Co., LTD. valued at $15.0 million (effective 2023-01-05).

Action: entry
Agreement: license
Counterparty: Kaken Pharmaceutical Co., LTD.
Value: $15.0 million
Effective: 2023-01-05

Exact text from the filing

On January 5, 2023, Spruce Biosciences, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Agreement”) with Kaken Pharmaceutical Co., LTD. (“Kaken”).

View on SEC.gov

76 material agreements filed in the last 30 days. Browse all material agreements →

SPRUCE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-000449

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.